- Home
- IPHA vs PIM Comparison
IPHA vs PIM Comparison
Compare IPHA & PIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- PIM
- Stock Information
- Founded
- IPHA 1999
- PIM 1988
- Country
- IPHA France
- PIM United States
- Employees
- IPHA N/A
- PIM N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- PIM Finance Companies
- Sector
- IPHA Health Care
- PIM Finance
- Exchange
- IPHA Nasdaq
- PIM Nasdaq
- Market Cap
- IPHA 148.3M
- PIM 157.1M
- IPO Year
- IPHA 2019
- PIM N/A
- Fundamental
- Price
- IPHA $1.79
- PIM $3.26
- Analyst Decision
- IPHA Strong Buy
- PIM
- Analyst Count
- IPHA 1
- PIM 0
- Target Price
- IPHA $11.50
- PIM N/A
- AVG Volume (30 Days)
- IPHA 779.8K
- PIM 57.5K
- Earning Date
- IPHA 09-12-2024
- PIM 01-01-0001
- Dividend Yield
- IPHA N/A
- PIM 8.28%
- EPS Growth
- IPHA N/A
- PIM N/A
- EPS
- IPHA N/A
- PIM 0.05
- Revenue
- IPHA $36,202,722.00
- PIM N/A
- Revenue This Year
- IPHA N/A
- PIM N/A
- Revenue Next Year
- IPHA $101.65
- PIM N/A
- P/E Ratio
- IPHA N/A
- PIM $63.80
- Revenue Growth
- IPHA N/A
- PIM N/A
- 52 Week Low
- IPHA $1.29
- PIM $2.90
- 52 Week High
- IPHA $3.51
- PIM $3.28
- Technical
- Relative Strength Index (RSI)
- IPHA 45.92
- PIM 48.03
- Support Level
- IPHA $1.64
- PIM $3.21
- Resistance Level
- IPHA $1.87
- PIM $3.28
- Average True Range (ATR)
- IPHA 0.12
- PIM 0.05
- MACD
- IPHA -0.04
- PIM -0.00
- Stochastic Oscillator
- IPHA 28.66
- PIM 68.75
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.